Galmed Pharmaceuticals Ltd(GLMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -13.81 | Insider Own | 3.07% | Shs Outstand | 1.0M | Perf Week | 17.96% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.0M | Perf Month | -2.42% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 3.95% | Short Float | 0.46% | Perf Quarter | 10.91% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.08 | Perf Half Y | -5.53% |
| Sales | 0.00B | P/B | 0.36 | EPS next 5Y | - | ROA | -55.03% | Short Interest | 0.00M | Perf YTD | -22.88% |
| Book/sh | 12.72 | P/C | 0.42 | EPS past 3/5Y | 73.46% 60.33% | ROE | -68.21% | 52W High | -64.92% ($13.20) | Perf Year | -60.22% |
| Cash/sh | 10.95 | P/FCF | - | Sales past 3/5Y | - | ROIC | -88.73% | 52W Low | 40.78% ($3.29) | Perf 3Y | -94.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 68.55% | Gross Margin | - | Volatility(W/M) | 6.83% 9.49% | Perf 5Y | -99.9% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.42 | Perf 10Y | -99.92% |
| Dividend Ex-Date | - | Quick Ratio | 4.16 | EPS Q/Q | 43.43% | Profit Margin | - | RSI (14) | 56.95 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.16 | Sales Q/Q | - | SMA20 | 9.31% ($4.24) | Beta | 0.65 | Target Price | $96 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/05/20 | SMA50 | 5.68% ($4.38) | Rel Volume | 4.95 | Prev Close | $3.83 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -12.95% ($5.32) | Avg Volume(3M) | 0.06M | Price | $4.63 |
| IPO | 2014/3/13 | Option/Short | No/Yes | Trades | 2306 | Volume | 288,501 | Change | 21.05% |
A clinical-stage biotech company headquartered in Israel. Its lead candidate, Aramchol, is an oral SCD1 modulator targeting non-alcoholic steatohepatitis (NASH/MASH) and liver fibrosis, and the company is a micro-cap stock that has advanced into Phase 3 clinical trials.
Over the past 1 year, on the lower side
65% below its 1-year high.
Traded more than usual That is 495% of its average volume.
GLMD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.0%.
Tap to view numbers
It ranks #552 of 593 in the industry
Based on market cap of $5M.
PCSA#550 Processa Pharmaceuticals Inc $5M PER - 
ONCO#551 Onconetix Inc $5M PER - GLMD#552 Galmed Pharmaceuticals Ltd $5M PER - 
GRI#552 GRI Bio Inc $5M PER - 
DRMA#553 Dermata Therapeutics Inc $5M PER - 
FAQ
What kind of company is GLMD?
GLMD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GLMD?
The market cap of GLMD is approximately $5M, ranking 5,695 within its sector.
What is the 52-week high and low for GLMD?
GLMD has recorded a 52-week high of $13.20 and a low of $3.29.
